Bernstein SocGen lowers Alnylam stock price target on valuation

Bernstein SocGen cut Alnylam's price target slightly to $447 from $448 while keeping an Outperform rating, citing strong U.S. momentum and Amvuttra beating consensus by 5%. The firm raised its FY2026 TTR estimate to $4,508 million, about 1% below management's guidance midpoint, and highlighted attractive valuation at under 7x EV/next-twelve-month sales with a PEG of 0.27. Separately, Alnylam reported Q1 2026 EPS of $1.99 versus $0.91 expected and revenue of $1.17 billion versus $1.12 billion expected, with quarterly net product revenue topping $1 billion for the first time.

Analysis

The market is still underestimating how much of ALNY’s re-rating is now driven by operating leverage rather than just top-line momentum. Once a rare-disease franchise crosses the billion-dollar quarterly revenue threshold, small incremental beats can translate into disproportionately better margin optics and cash generation, which is why the stock can absorb skepticism about geographic mix better than a typical launch story. The key second-order effect is that every proof point of durable U.S. share gain compresses the perceived risk premium around future launches, especially for a platform that investors had previously treated as execution- and reimbursement-fragile.

The bearish debate is really about sustainability versus one-quarter acceleration, and that matters because valuation will hinge on whether growth normalizes or compounds into 2026. If outside-U.S. launches keep outperforming while U.S. share keeps widening, the multiple can expand even if consensus EPS moves only modestly; if not, the stock becomes vulnerable to a fast de-rating because current expectations already imply a lot of future success. The market is also likely assigning too much binary weight to the competitor readthrough, when in practice class-level sentiment can move both names together even if near-term trader positioning tries to force a relative-value divergence.

For IONS, the setup is more interesting as a hedge than a standalone short. Any disappointment in ALNY’s durability would likely spill over into the broader RNA-therapeutics tape, but the reverse is also true: if ALNY keeps delivering, IONS can benefit from sector sympathy even without a comparable fundamental inflection. The consensus may be missing that “good enough” growth plus improving margins is often enough to sustain multiple expansion in a scarce-growth biotech, particularly when the company is still early in monetizing its platform outside the U.S.

Catalyst timing is mostly 1-3 months for sentiment re-rating and 6-12 months for valuation compounding. The main reversal risk is a deceleration in sequential revenue growth that exposes how much of the current debate is about launch timing rather than underlying demand. If the next two quarters show clean U.S. durability and continued ex-U.S. upside, the stock should trade more like a category winner than a one-time beat story.

Key Decisions for Investors

• Go long ALNY on pullbacks over the next 1-2 weeks; target a 3-6 month hold. Risk/reward is attractive if sequential revenue stays firm, because a modest multiple expansion can outrun consensus EPS revisions.
• Use IONS as a tactical pair leg: long ALNY / short IONS for 1-3 months if you expect the market to reward execution quality over platform sympathy. Stop if IONS starts trading as a clean sympathy beneficiary from broader RNA optimism.
• If already long ALNY, buy downside protection via 2-3 month puts financed with upside calls to express a 'good-but-not-perfect' thesis. This protects against the key risk: sequential growth disappointment despite strong annual growth.
• Add only on confirmation of follow-through in the next quarterly print; do not chase after a single beat. The setup improves materially if guidance is revised up again, but the stock is vulnerable if the midpoint stays ahead of visible quarterly cadence.
• For relative value, fade any sharp ALNY/IONS divergence in either direction; the better trade is the spread, not outright beta, because class sentiment can override single-name fundamentals in the short run.